Emerging Precision Therapy for Multiple Sclerosis Using Chimeric Autoantigen-T Cell Receptor (CATCR)
|
الباحثون المشاركون |
آية شموط |
|
منشور في |
International Journal of High School Research, volume 7, issue 1, p. 7-13, January 2025. |
|
الملخص |
With the rise of precise cellular and immunotherapies for autoimmune diseases, multiple sclerosis presents a challenge for researchers due to its complexity, which includes multiple pathogens and the difficulty of detecting specific autoantibodies for this condition. As a result, current treatments rely on suppressive immunity, leading to a weakened immune system in patients, which increases the risk of infections and reduces anti-tumor immunity. In this review, we will focus on the role of B cells and autoantibodies in multiple sclerosis. We will discuss the efficacy of Chimeric Autoantigen T Cell Receptor Therapy in anti phospholipid syndrome, and suggest following the same approach to treat MS. We will discuss methodologies to identify the patient’s specific auto-antigens to incorporate them into T cell receptors using CRISPR, and explore the potential therapeutic benefits as well as the associated side effects for CAR T Cell and CATCR therapies. Finally, we will highlight two in progress and approved immunotherapies for multiple sclerosis. KEYWORDS: Biomedical and Health Sciences, Immunology, Multiple Sclerosis, B Cells; Immunotherapies. |
|
رابط البحث كاملاً |
